UK-US trade deal will lead to more than 200k avoidable deaths
Analysis suggests the UK-US trade deal could lead to 229,000 excess deaths in England over a decade by increasing US drug imports and reducing medicine pricing controls. The findings raise concerns about public health impacts from the agreement's pharmaceutical provisions.
Background
- The analysis suggests a UK-US trade deal that lowers drug prices in the US but raises them in the UK could cause 229,000 excess deaths in England over a decade — primarily because the NHS would likely pay more for medicines, reducing its ability to fund care and leading to worse health outcomes.
- The US has long sought greater access to Britain's pharmaceutical market. The NHS uses its single-payer bargaining power to negotiate lower drug prices; US trade negotiators have pushed to weaken this, fearing it undermines American drug companies' profits.
- The figures come from modelling by academics, not a government study. The mechanism is indirect: higher drug costs would squeeze NHS budgets, forcing cuts elsewhere (staff, equipment, other treatments), which in turn reduces life expectancy.
- This is a live policy debate. The UK left the EU partly to pursue independent trade deals; supporters of a US deal argue it would boost growth, while critics say it would jeopardise the NHS's founding principle of care based on need, not ability to pay.